Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|BRAF V600E||lung non-small cell carcinoma||sensitive||Vemurafenib||Guideline||Actionable||Zelboraf (vemurafenib) is in guidelines for metastatic non-small cell lung cancer patients with BRAF V600E mutations who can not tolerate the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) (NCCN.org).||detail...|
|BRAF V600E||lung non-small cell carcinoma||sensitive||Vemurafenib||Phase II||Actionable||In a Phase II trial (VE-BASKET), responses were seen in patients with non-small cell lung cancer harboring BRAF V600E (n=63) when treated with Zelboraf (vemurafenib), including 23 patients with a partial response (PMID: 32029534; NCT01524978).||32029534|
|BRAF V600E||lung non-small cell carcinoma||sensitive||Vemurafenib||Case Reports/Case Series||Actionable||In a clinical case study, a non-small cell lung cancer patient harboring a BRAF V600E mutation had a complete response after treatment with Zelboraf (vemurafenib) (PMID: 23733758).||23733758|
|BRAF V600E||lung non-small cell carcinoma||sensitive||Vemurafenib||Phase II||Actionable||In a Phase II trial (MyPathway), Zelboraf (vemurafenib) treatment resulted in an objective response of 43% (6/14, 1 complete response, 5 partial response) in patients with non-small cell lung cancer harboring BRAF V600E, and stable disease lasting more than 120 days in 2 patients (PMID: 29320312; NCT02091141).||29320312|
|BRAF V600E||lung non-small cell carcinoma||sensitive||Vemurafenib||Clinical Study||Actionable||In a retrospective analysis, non-small cell lung cancer patients harboring BRAF V600E achieved an overall response rate of 54% (13/24, 2 complete responses, 11 partial responses, and 10 with stable disease) and a disease control rate of 96% following treatment with Zelboraf (vemurafenib) (PMID: 26200454).||26200454|
|PubMed Id||Reference Title||Details|
|(23733758)||Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma.||Full reference...|
|(29320312)||Targeted Therapy for Advanced Solid Tumors on the Basis of Molecular Profiles: Results From MyPathway, an Open-Label, Phase IIa Multiple Basket Study.||Full reference...|
|(26200454)||Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort.||Full reference...|
|(32029534)||Pan-Cancer Efficacy of Vemurafenib in BRAFV600-Mutant Non-Melanoma Cancers.||Full reference...|